Lataa...
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan
BACKGROUND: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. METHODS: This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat’s noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemi...
Tallennettuna:
| Julkaisussa: | J Am Soc Nephrol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Nephrology
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7350993/ https://ncbi.nlm.nih.gov/pubmed/32493693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019060623 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|